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Which Prior Knowledge? Quantification of In Vivo Brain
13C MR Spectra Following 13C Glucose Infusion Using
AMARES
Bernard Lanz,1,2 Joa˜o M. N. Duarte,1,2 Nicolas Kunz,1,3 Vladimir Mlynarik,1
Rolf Gruetter,1,4,5 and Cristina Cudalbu1*
The recent developments in high magnetic field 13C magnetic res-
onance spectroscopy with improved localization and shimming
techniques have led to important gains in sensitivity and spectral
resolution of 13C in vivo spectra in the rodent brain, enabling the
separation of several 13C isotopomers of glutamate and glutamine.
In this context, the assumptions used in spectral quantification
might have a significant impact on the determination of the 13C
concentrations and the related metabolic fluxes. In this study, the
time domain spectral quantification algorithm AMARES (advanced
method for accurate, robust and efficient spectral fitting) was
applied to 13C magnetic resonance spectroscopy spectra acquired
in the rat brain at 9.4 T, following infusion of [1,6-13C2] glucose.
Using both Monte Carlo simulations and in vivo data, the goal of
this work was: (1) to validate the quantification of in vivo 13C iso-
topomers using AMARES; (2) to assess the impact of the prior
knowledge on the quantification of in vivo 13C isotopomers using
AMARES; (3) to compare AMARES and LCModel (linear combina-
tion of model spectra) for the quantification of in vivo 13C spectra.
AMARES led to accurate and reliable 13C spectral quantification
similar to those obtained using LCModel, when the frequency shifts,
J-coupling constants and phase patterns of the different 13C iso-
topomers were included as prior knowledge in the analysis. Magn
Reson Med 69:1512–1522, 2013.VC 2012 Wiley Periodicals, Inc.
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INTRODUCTION
In vivo dynamic 13C magnetic resonance spectroscopy
(MRS) together with the administration of 13C-enriched
substrates is a powerful and unique technique to noninva-
sively investigate brain metabolites and metabolic fluxes
related to enzyme activities in the in vivo brain (1–6). In
particular, the measurement of 13C incorporation into dif-
ferent carbon positions of glutamate and glutamine in con-
junction with an appropriate mathematical model of com-
partmentalized cerebral metabolism (2,4) allowed the
quantitative measurement of important pathways involved
in energy metabolism including, but not limited to: glycoly-
sis, tricarboxylic acid (TCA) cycle, malate-aspartate shuttle
activity and the glial pyruvate carboxylase. In addition, the
glutamate-glutamine cycle between neurons and astrocytes
can be measured (1–4,7–13). Further separation of the glial
and neuronal TCA cycle activities is possible when meas-
uring the C3 and C2 positions of glutamate and glutamine,
due to the glial-specific activity of pyruvate carboxylase,
diluting the position 3 and labeling the position 2 of glial
glutamate (2) when infusing [1,6-13C2] glucose.
The main advantage of 13C MRS stands mainly in its
increased chemical shift dispersion allowing the detec-
tion not only of different molecules but also of specific
carbon positions within the same molecule (the so-called
13C isotopomers) (above 150 ppm – carbon atoms in car-
bonyl groups; 100–60 ppm – carbon atoms in hydroxyl
groups; 60–45 ppm – carbon atoms in CH groups; 45–25
ppm – carbon atoms in CH2 groups and below 25 ppm –
carbon atoms in CH3 groups). The low sensitivity of in
vivo 13C MRS can be overcome by the use of 13C-
enriched substrates. In animals, widely used 13C-
enriched substrates are [1-13C] or [1,6-13C2] glucose.
[1,6-13C2] glucose gives a labeling pattern similar to
[1-13C] glucose, however the fractional enrichment (FE)
of pyruvate (and of all subsequent metabolic pools) can
be twice as high, thus improving the detection sensitiv-
ity. Moreover, the probability of 13C isotopes in adjacent
positions increases (by a factor of four for two adjacent
carbon positions) and consequently the splitting of
resonances due to homonuclear 13C-13C scalar coupling
giving rise to isotopomer resonances becomes more im-
portant. Recently, other 13C-enriched substrates have
also been used (i.e., [2-13C] glucose, [2-13C] acetate) to
discriminate glial and neuronal metabolism (3,14,15).
In the past decade, the measurements at high magnetic
fields combined with improvements in localization tech-
niques and with excellent shimming have led to impor-
tant gains in sensitivity and spectral resolution of 13C in
vivo spectra (1,2,13–16). Signals from 18 different
resonances can be detected in the in vivo rat brain after
infusion of [1,6-13C2] glucose. Among these resonances,
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the signals of alanine (Ala), lactate (Lac), N-acetylaspar-
tate, g-aminobutyrate, glutamine (Gln), glutamate (Glu),
aspartate (Asp), glucose (Glc) labeled at different carbon
positions were measured (1,2,9,16,17). Consequently, the
amount of information that can be obtained from in vivo
13C spectra has considerably increased (i.e., signals from
different carbon positions combined with a fine structure
arising from 13C-13C J-couplings) (17).
To quantify 13CMRS spectra, methods based on the incor-
poration of prior knowledge improved quantification, espe-
cially in the presence of overlapping signals (17). In a recent
study (17) it has been shown that LCModel analysis com-
bined with a simulated basis set of each isotopomer with
appropriate chemical shift and J-coupling pattern allows ro-
bust and reliable dynamic 13C isotopomers analysis in the
in vivo rat brain at 9.4T. Thus, LCModel has become popu-
lar in quantifying in vivo 13C spectra. LCModel has an im-
portant number of attractive features, but for the quantifica-
tion of 13C spectra it requires significant adjustments (i.e., of
the control file) to adapt the original program to 13C data. In
addition, it also requires a specific basis set of each iso-
topomer with appropriate chemical shift and J-coupling pat-
tern. AMARES, an improved interactive time domain
method for accurate and efficient parameter estimation of
MRS signals with use of prior knowledge (18), represents an
alternative approach to LCModel for the quantification of in
vivo 13C spectra, since in vivo 13C spectra are typically char-
acterized by flat baseline and increased chemical shift dis-
persion. One of the main advantages relies in the fact that
no simulated metabolite basis set is needed when quantify-
ing the in vivo spectra. The signals (resonances) to be quan-
tified are manually selected and the prior knowledge is
given in terms of relative or fixed amplitudes, frequencies,
linewidths, phases and lineshapes. This advantage
increases the flexibility for the user, and consequently any
error created by the user can additionally lead to unreliable
metabolite quantification. Moreover, fitting the signals aris-
ing from different carbon positions with singlets and
neglecting the multiplets due to 13C-13C J-couplings might
lead to substantial errors in the quantification of the time
courses which would consequently lead to errors in the esti-
mated metabolic fluxes. To the best of our knowledge the
impact of prior knowledge in AMARES has never been
reported for quantification of 13C isotopomers in the in vivo
rat brain at high magnetic field.
Therefore, the purpose of this study was: (1) to assess
the impact of the prior knowledge on the quantification of
in vivo 13C isotopomers using AMARES combined with
low-level to high-level prior knowledge; (2) to validate
the quantification of in vivo 13C isotopomers using
AMARES; and (3) to compare AMARES and LCModel for
the quantification of in vivo 13C spectra. The impact of
the prior knowledge on quantification and the validation
of AMARES were performed using Monte Carlo simula-
tions and in vivo quantifications at 9.4T in the rat brain.
METHODS
Animals
All experimental procedures involving animals were
approved by the local ethics committee. In vivo localized
13C spectra were acquired on Sprague-Dawley rats (275
to 325g, n ¼ 4) fasted overnight. The rats were intubated
and artificially ventilated with 2% isoflurane (Attane,
Minrad, NY) during the surgery. The left and right femo-
ral arteries and veins were catheterized for monitoring
blood gases, blood pressure, glucose concentration, and
for infusion of a-chloralose (Acros Organics, Geel, Bel-
gium) and [1,6-13C2] glucose (Isotec, Sigma-Aldrich,
Basel, Switzerland). After preparation, anesthesia was
switched from isoflurane to a-chloralose by injecting an
initial 80 mg/kg bolus of a-chloralose, followed by continu-
ous infusion at a rate of 26.7 mg/kg/h (2). The animals
were placed in a home-built holder with the head stereo-
taxically immobilized. Respiration rate and blood pressure
were measured throughout the experiment (SA Instru-
ments, NY). Body temperature was measured with a home-
built rectal probe and maintained stable at 38C 6 0.5C
using a heated water circuit. Arterial blood was sampled
approximately every 30 min to monitor blood gases (AVL
Compact 3, Diamond Diagnostics, MA) and measure
plasma glucose (Reflotron Plus analyzer, Roche Diagnos-
tics GmbH, Mannheim, Germany) and lactate (GW7 Micro-
Stat, Analox Instruments, London, UK) concentrations.
The glucose infusion protocol was adapted from previ-
ous studies (1,2,16) to achieve a fast increase to a stable
level of plasma glucose FE (step function). An exponen-
tially decaying bolus of 99%-enriched [1,6-13C2] glucose
solution (1.1 M in a saline solution) was administrated
over 5 min. The volume of this bolus was adapted to the
measured glycemia to achieve a 70% plasma fractional
enrichment at the end of the 5 minutes. A continuous
infusion of 70%-enriched glucose was further applied
for the remaining 6 h. Glucose was infused at a rate ad-
justable to the concomitantly measured plasma glucose
concentrations to maintain the desired glycemia levels
(around 300 mg/dL).
1H and 13C MRS
Localized 13C spectra were acquired on a Varian Direct
Drive (Palo Alto, CA) console interfaced to an actively
shielded 9.4T magnet (Magnex Scientific, Oxford, UK)
with a 31-cm horizontal bore. The magnet was equipped
with 12 cm inner-diameter actively shielded gradient
sets giving a maximum gradient of 400 mT/m in 120 ms.
Acquisitions were done using: a home-built 10 mm
(13C)/13 mm (1H quad) surface coil as radiofrequency
transceiver. The rat brain was positioned in the isocenter
of the magnet and fast-spin-echo images (repetition time
¼ 4 s, echo time ¼ 52 ms, slice thickness of 1 mm and
an in plane resolution of 94 mm) were acquired to deter-
mine anatomical landmarks and further position the vol-
ume of interest, consisting of a 320 mL voxel (5  8  8
mm3) in the brain. The static field homogeneity was
adjusted using first- and second-order shims with FAST-
MAP (19,20). To measure the total concentration of the
metabolites of interest, 1H MRS spectra were acquired
before starting glucose infusion using the SPECIAL
sequence (21) (repetition time ¼ 4 s, echo time ¼ 2.8 ms,
160 averages, 5  8  8 mm3). The 13C MRS dynamic ac-
quisition was performed in the same voxel (320 mL) with
a temporal resolution of 5.4 min, using the semiadiabatic
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distortionless enhancement by polarization transfer
(DEPT) technique (repetition time ¼ 2.5 s, interpulse
delay 3.8 ms (JCH¼ 130 Hz), 45 for last 1H pulse to
simultaneously measure signals from CH, CH2, CH3
groups) (16). Localization was performed using 3D-ISIS
(image selected in vivo spectroscopy) (hyperbolic secant
inversion pulses (22), 2 ms duration, 8 kHz bandwidth)
combined with outer volume suppression (23).
Data Analysis
In vivo 13C spectra were quantified using four
approaches (1st, 2nd, and 3rd approach based on
AMARES (18) and 4th approach based on LCModel
(24,25) used as a ‘‘gold standard’’ for validation pur-
poses). In this study, we fitted only the isotopomers of
Glu C4, C3, C2 and of Gln C4, C3, C2 since their time
courses are the principal ones used for metabolic model-
ing. Henry et al. (17) showed that accurate quantification
of aspartate can be obtained at 9.4T with a temporal re-
solution of 22 min, whereas 1 h accumulation was neces-
sary for g-aminobutyrate. Increasing the magnetic field to
14.1T allowed quantification of aspartate with a temporal
resolution of 5.3 min, as shown by Duarte et al. (2), but
the estimated fluxes did not change significantly with
the inclusion of aspartate turnover curves.
1. 1st approach: AMARES with low-level prior knowl-
edge: each resonance at a specific carbon position
(Glu C4, C3, C2 and Gln C4, C3, C2) was fitted using a
singlet without any information on the J-coupling pat-
tern (for example, the multiplets of Glu at the position
4 were fitted using only one singlet). The following
constraints were used: relative phases (fixed to zero)
and Lorentzian lineshape. No constraints were given
on the amplitudes, linewidths or frequencies.
2. 2nd approach: AMARES combined with medium-level
prior knowledge, identical with that used by LCModel
(isotopomers with the same chemical shift and J-cou-
pling pattern, see Table 1) with the exception that the
information on the relative phases (due to homonu-
clear 13C-13C J-modulation occurring during the delay
between the 13C excitation and acquisition in the
DEPT sequence) was neglected, i.e., the relative
phases was fixed to zero. Each isotopomer was fitted
using lorentzian lines with the following constraints:
• linewidths: the linewidth of the GluC4 singlet was
estimated, whereas for the other isotopomers we
considered identical linewidths to that of the GluC4
singlet.
• amplitudes: for the singlets the amplitudes were
estimated, whereas for the doublets or triplets prior
knowledge was given as following: the doublets
peaks were considered as having equal amplitudes
by using the ‘‘fixed ratio’’ option, and for the trip-
lets we considered the relative intensities of 1:2:1
using the same option.
• frequencies: soft constraints were given to all the
singlets (60.05 Hz) and the J couplings were
included using the singlets as reference and the
‘‘fixed shift’’ option.
More details regarding the prior knowledge can be
found in the Table 1.
Table 1
Details on the High-Level Prior Knowledge Used in AMARES for the Quantifications with the 2nd and 3rd Approach
Resonance Multiplet Frequency Relative phase Amplitude
GlnC3 GlnC3S 27.15–27.25 ppm 0.0 Estimated
GlnC3D-1 GlnC3S–18.45 Hz 34.6 Estimated
GlnC3D-2 GlnC3Sþ16.45 Hz 34.6 GlnC3D-1*1.0
GlnC3T-1 GlnC3Sþ32.9 Hz 69.1 GlnC3T-2*0.5
GlnC3T-2 GlnC3S–2 Hz 0.0 Estimated
GlnC3T-3 GlnC3S–36.9 Hz 69.1 GlnC3T-2*0.5
GluC3 GluC3S 27.8–27.9 ppm 0.0 Estimated
GluC3D-1 GluC3Sþ16.3 Hz 34.3 Estimated
GluC3D-2 GluC3S–18.3 Hz 34.2 GluC3D-1*1.0
GluC3T-1 GluC3S–2 Hz 0.0 Estimated
GluC3T-2 GluC3Sþ32.6 Hz 68.5 GluC3T-1*0.5
GluC3T-3 GluC3S–36.6 Hz 68.5 GluC3T-1*0.5
GlnC4 GlnC4S 31.74–31.84 ppm 0.0 Estimated
GlnC4D43-1 GlnC4S–18.45 Hz 34.6 Estimated
GlnC4D43-2 GlnC4Sþ16.45 Hz 34.6 GlnC4D43-1*1.0
GluC4 GluC4S 34.3–34.4 ppm 0.0 Estimated
GluC4D43-1 GluC4Sþ16.3 Hz 34.3 Estimated
GluC4D43-2 GluC4Sþ18.3 Hz 34.3 GluC4D43-1*1.0
GlnC2 GlnC2S 55.15–55.25 ppm 0.0 Estimated
GlnC2D23-1 GlnC2Sþ17.45 Hz 34.6 Estimated
GlnC2D23-2 GlnC2S–17.45 Hz 34.6 GlnC2D23-1*1.0
GlnC2D21-1 GlnC2Sþ25.7 Hz 0.0 Estimated
GlnC2D21-2 GlnC2S–27.7 Hz 0.0 GlnC2D21-1*1.0
GluC2 GluC2S 55.65–55.75 ppm 0.0 Estimated
GluC2D23-1 GluC2Sþ16.3 Hz 34.3 Estimated
GluC2D23-2 GluC2S-18.3 Hz 34.3 GluC2D23-1*1.0
GluC2D21-1 GluC2Sþ25.7 Hz 0.0 Estimated
GluC2D21-2 GluC2S–27.7 Hz 0.0 GluC2D21-1*1.0
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3. 3rd approach: AMARES combined with high-level
prior knowledge, identical with that used by LCModel
and by our 2nd approach (isotopomers with the same
chemical shift and J-coupling pattern, see Table 1)
with additional constraints on relative phases.
• relative phases: the effect of homonuclear 13C-13C J-
evolution during the DEPT sequence was taken into
account as described previously (17). The relative
phases were calculated for each multiplet. For a tri-
plet the relative phases were calculated as y0:0:y0,
with y0¼ 2p*t*JCC radians. The relative phases for
doublet were y0:y0, with y0¼ p*t*JCC radians. The
delay t was fixed empirically as previously deter-
mined (17).
The AMARES files containing the prior knowledge
used for the 3rd approach are provided as Supporting
Information.
4. 4th approach: LCModel combined with a basis set
generated using Matlab by simulating each isotopomer
with the appropriate chemical shift and J-coupling
pattern, as previously described by Ref. 17. The line-
shapes were Lorentzian with a linewidth of 4 Hz.
Notations: for consistency similar notations as those
used by Refs. 17 and 26 were used in this study. For
example, for the glutamate at the position C4 we used
GluC4S to designate the singlet and GluC4D43-1 and
GluC4D43-2 represent the two lines of the doublet. Over-
all, a specific multiplet was named using the abbreviation
of the metabolite (i.e., Glu for glutamate), followed by the
labeled position (i.e., C4 – to indicate the labeling at the
carbon position 4) and the specific multiplet structure
(i.e., S-singlet, D-doublet, with D43 representing the dou-
blet corresponding to the coupling to the C3, T-triplet and
DD-doublet of doublet). As for the previous studies (17)
no numbers were added when the coupling constants
were identical (i.e., GluC3D is the sum of GluC3D32 and
GluC3D34). In addition, GluC4 refers to the sum of all glu-
tamate isotopomers labeled at the position C4.
Some isotopomers were excluded from this study
since their probability of being labeled was very low:
GluC4D45—doublet of GluC4 corresponding to the cou-
pling between the positions 4 and 5; GluC4DD—doublet
of doublet for GluC4 corresponding to the coupling
between the positions 3, 4, and 5; GluC2DD—doublet of
doublet for GluC2 corresponding to the coupling
between the positions 1, 2, and 3; GlnC2DD—doublet of
doublet for GlnC2 corresponding to the coupling
between the positions 1, 2, and 3. The criteria for
excluding these isotopomers was based on the fact that
when infusing [1,6-13C2] glucose the positions 1 and 5
are not sufficiently labeled to give a detectable signal in
vivo within 5 min of time resolution and consequently
their inclusion as prior knowledge would increase the
number of parameters to estimate and therefore the
incertitude of the quantification. In addition, these
isotopomers were neither fitted when using LCModel.
Brain Metabolism of [1,6-13C2] Glucose
After transport across the blood brain barrier, glucose is
metabolized to pyruvate through the glycolysis (27). In the
case of [1,6-13C2] glucose, two molecules of [3-
13C] pyru-
vate are generated from one molecule of labeled glucose.
Pyruvate is metabolized both in the glial and neuronal
TCA cycles. When infusing [1-13C] glucose, only one mole-
cule of [3-13C] pyruvate is produced, while the second py-
ruvate molecule generated by the glycolysis is unlabeled.
Brain metabolism of [1,6-13C2] glucose and the result-
ing labeling of the carbon positions in the glutamate and
glutamine molecules are illustrated in Fig. 1. The 13C
carbon from [1,6-13C2] glucose reaches the position C4 of
2-oxoglutarate, which exchanges label with the position
C4 of cytosolic glutamate trough transmitochondrial
exchange. In the second turn of the TCA cycle, through
the same exchange process, half of the 13C further
reaches the position C3 of glutamate and the other half
the position C2. In the third turn of the TCA cycle, the
position C1 of glutamate gets also labeled, but this posi-
tion is usually not simultaneously measurable with the
positions C4, C3, and C2 using 13C MRS, due to the large
chemical shift of the C1 carbon signal relative to the
other resonances. Some reactions are specific to glial
FIG. 1. Description of the 13C labeling of glutamate and glutamine
through brain metabolic processes. PC: pyruvate carboxylase,
PDH: pyruvate dehydrogenase (a) two-compartment description
of brain glucose metabolism. Glutamate and glutamine are part of
the neurotransmission cycle, which interacts both with the neuro-
nal and glial TCA cycles; (b) Detail of the transfer of 13C to the dif-
ferent carbon positions of glutamate in the TCA cycle. PC is only
taking place in the glial TCA cycle. Through the neurotransmission
cycle, the glutamine molecules get labeled at the same carbon
positions than their respective glutamate precursor; (c) Chemical
structures of glutamate and glutamine with their corresponding
carbon positions. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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cells, like pyruvate carboxylase. This reaction brings 13C
from [3-13C] pyruvate to the position 2 of glial glutamate
and unlabeled 12C to the position 3 of glial glutamate.
Additionally, the glial Acetyl-CoA, at the entrance of the
TCA cycle, is diluted by alternative energetic fuels that
glial cells can metabolize, like acetate and fatty acids
(28,29).
The neurotransmission cycle, or glutamate-glutamine
cycle, brings 13C from glial glutamate to glutamine and
further to neuronal glutamate, which labels again glial
glutamate. No labeling exchange between the different
carbon positions takes place in this cycle, as opposed to
the TCA cycles.
The dynamics of labeling of glutamate and glutamine
contains information on the glial and neuronal TCA
cycles activity and on the neurotransmission cycle (4).
The total concentration of 13C at a certain carbon posi-
tion is given by the total intensity of the corresponding
13C resonance, independently of its multiplet structure.
The percentage of molecules labeled at a certain carbon
position, known as fractional enrichment, is directly
related to the multiplet pattern of the corresponding res-
onance (30). Therefore, infusing [1-13C] glucose instead
of [1,6-13C2] glucose will decrease by a factor 2 the frac-
tional enrichment of each carbon position leading to a
decrease by a factor 4 of the doublet intensities and by a
factor 8 of the triplet intensities. In the case of [1,6-13C2]
glucose infusion, the quantification of the multiplets
structure is therefore more critical.
Monte Carlo Simulations
To estimate the reliability of the estimated concentra-
tions in different experimental conditions, artificial 13C
MRS spectra representative of brain in vivo spectra
obtained at labeling steady-state were simulated with dif-
ferent linewidths and signal to noise ratios (SNRs). The
simulated spectra were generated using Matlab (Math-
Works, Natick, MA). Each resonance was constructed
using previously measured values of the chemical-shift
and J-coupling of the different isotopomers measurable
in an in vivo spectrum (17) (typically 20 isotopomers of
Glu C4, C3, C2 and of Gln C4, C3, C2). For each iso-
topomer, the corresponding peaks were created by con-
structing an FID simulated as an oscillating function
multiplied by a decaying real exponential function to
generate a Lorentzian lineshape with the desired line-
width, frequency and phase, determined as described in
Table 1 and in the method 2 of the AMARES data analy-
sis. The FID of each isotopomer was further scaled (rela-
tively to the GluC4S singlet) to the corresponding signal
intensity measured in a typical in vivo brain 13C spec-
trum. This was done in the following way: using typical
brain metabolic fluxes (2) and total brain metabolite con-
centrations, the fractional enrichment at labeling steady-
state (280 mins) of the different carbon positions of glu-
tamate and glutamine was calculated. From these frac-
tional enrichments, the amplitude of each isotopomer
was calculated as the product of the probabilities of hav-
ing the corresponding carbons of a molecule labeled and
the other neighboring carbons of the same molecule
unlabeled. For example, the intensity of the isotopomer
GluC3D34 was calculated as the product of the FE of the
position C3 and the FE of the position C4 of glutamate,
multiplied by (1-FEC2). In this particular case, since the
chemical shift and J-coupling of the isotopomer
GluC3D32 are the same as for GluC3D34, both calculated
intensities were added to generate the doublet GluC3D,
with half of the summed intensity in each of the two
resonances of the doublet.
Based on phantom experiments, the relative iso-
topomer intensities were further corrected to simulate
the detection efficiency of the corresponding resonances
by the DEPT sequence at the different chemical shifts,
when placing the carrier frequency at 41 ppm.
A random normally distributed noise was added to the
sum of the FIDs of each isotopomer. The noise level of the
simulated spectra was expressed in terms of SNR, calcu-
lated as the peak height of the GluC4S singlet (the highest
peak present in a 13C spectrum following [1,6-13C2] glu-
cose infusion) divided by twice the root mean square
noise. The resulting FID was finally Fourier transformed,
resulting in an artificial steady-state 13C spectrum.
To compare accuracy and precision of the three differ-
ent spectral quantification approaches using AMARES
(1st, 2nd, and 3rd approach) and consequently the
impact of prior knowledge, 200 spectra were generated
with a SNR of 10 and a linewidth of 5 Hz and fitted
using each of the four methods.
In a second step, the effect of the spectral quality on
the quantification was analyzed using different values
for the SNR and linewidth (i.e., ranging from poor qual-
ity data at SNR of 1 or 2 and linewidth of 10 Hz to good
quality data at SNR of 10 and linewidth of 5 Hz). The
3rd approach (AMARES combined with high-level prior
knowledge) was selected to analyze changes in the preci-
sion and accuracy of the spectral quantification of the
carbon positions GluC4, C3, and C2 as well as GlnC4,
C3, C2, when decreasing SNR or increasing linewidth.
Monte Carlo simulations (based on 200 artificial spectra)
were undertaken with a varying SNR of 1, 2, 3, and 10
and a linewidth of 5 Hz. The effect of the linewidth on
the quantification was further analyzed with Monte
Carlo simulations by increasing linewidth from 5 to 10
Hz, both in the case of a SNR of 3 and 10. Finally, the
spectra at SNRs of 1 and 2 and linewidths of 5 and 10
Hz were used to compare the 1st (low-level prior knowl-
edge) and 3rd (high-level prior knowledge) approaches
using AMARES, to evaluate the impact of prior knowl-
edge on processing poor quality data (low SNR and large
linewidths) and to assess whether the two approaches
give similar results at low SNR.
The mean and standard deviation of the fitted peak
intensities obtained over 200 spectra were reported and
compared to the true peak intensities used for the gener-
ation of the artificial spectra. For each metabolite, the
bias (difference between the mean value of the amplitude
estimates and the true amplitude) was expressed as a
percentage of the true amplitude. A positive bias corre-
sponds to an overestimation of the amplitude compared
with the true value, and a negative bias to an underesti-
mation of the amplitude. In addition, the standard devia-
tions were expressed as a percentage of the mean values
of the amplitude estimates.
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RESULTS
First, Monte Carlo simulations were performed to assess
the influence of prior knowledge by quantifying the
simulated Monte Carlo signals with the different
approaches using AMARES: from low-level to high-level
prior knowledge (1st, 2nd, and 3rd approach). In addi-
tion, the reliability and robustness of 13C isotopomers
quantification using AMARES with high-level prior
knowledge (3rd approach) was evaluated using different
levels of SNR and linewidth. Finally, the impact of prior
knowledge on poor quality data was assessed by compar-
ing the 1st (low-level prior knowledge) and 3rd (high-
level prior knowledge) approaches using AMARES at
SNRs of 1 and 2.
Figure 2a shows the influence of prior knowledge by
quantifying the Monte Carlo signals with the different
approaches, from low-level to high-level prior knowledge
using AMARES (1st, 2nd, and 3rd approach). As can be
seen, when low-level prior knowledge was used, mean-
ing that each resonance at a specific carbon position was
fitted using a singlet without any information on the J-
coupling pattern, higher underestimation were obtained
for all metabolites (3–42%) except of GluC3 which was
overestimated by 23%. The standard deviations were on
the order of 2%, meaning that no important variations
were obtained. To further evaluate the impact of the
prior knowledge, we slightly improved our prior knowl-
edge by adding each isotopomer with chemical shift and
FIG. 2. Effects of increasing prior knowl-
edge in AMARES analyzed with Monte
Carlo simulations: (a) Quantifications per-
formed using AMARES with the 1st, 2nd,
and 3rd approach; (b) and (c) Quantifica-
tions performed using AMARES combined
with high-level prior knowledge (3rd
approach) for different SNRs and line-
widths; (d) Quantifications performed using
AMARES 1st and 3rd approach on signals
with an SNR of 1 and linewidth of 5 Hz; (e)
Quantifications performed using AMARES
1st and 3rd approach on signals with an
SNR of 2 and linewidth of 10 Hz.
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J-coupling information but neglecting the relative phases
due to homonuclear 13C-13C J-modulation occurring dur-
ing the delay between the 13C excitation and acquisition
in the DEPT sequence (medium-level prior knowledge,
2nd approach). In this second case the results showed
important improvements but slight overestimations rang-
ing from 3 to 11% were still obtained for all the metabo-
lites with the exception of Gln C2 and C3 which were
underestimated by 4%. These over/underestimations
were also clearly visible in Fig. 3b when looking at the
quantification residue. Finally, the 3rd approach with
high-level prior knowledge gave consistent and highly
similar results to the true values. No under/overestima-
tions were observed and the standard deviations were
about 1–2%. The quality of the AMARES fit with high-
level prior knowledge was excellent as shown in Fig. 3a.
The reliability and robustness of 13C isotopomers
quantification using AMARES with high-level prior
knowledge (3rd approach) and different levels of SNR
and linewidth is shown in Fig. 2b,c. All metabolites
were identified using AMARES with high-level prior
knowledge (3rd approach), even with small levels of
SNR and large linewidths. Overall, for SNRs of 10 and 3
with linewidth between 5 and 10 Hz, the systematic
errors were within 2%, well within typical experimental
errors. At a very low sensitivity (SNR of 1) the errors
increased to 7%. As expected, larger standard deviations
(4–16%) were observed with lower SNRs and larger
linewidths.
The impact of prior knowledge on poor quality data
(SNR of 1 and 2 with linewidth of 5 and 10 Hz) is shown
in Fig. 2d,e. All metabolites were correctly identified
when using AMARES with high-level prior knowledge
(3rd approach) even with the lowest SNR of 1. System-
atic errors were within 7% and standard deviations
between 4 and 16%. However, when using AMARES
with low-level prior knowledge (1st approach), system-
atic errors increased to 30%.
Figures 4 and 5 show the overall quality of in vivo 13C
spectra acquired in this study at 9.4T in the rat brain. In
vivo spectra contained a considerable amount of infor-
mation: resonances from glucose C6, glutamate and glu-
tamine C4, C3, C2, aspartate C3, C2 were detected to-
gether with smaller resonances from g-aminobutyrate, N-
acetylaspartate, aspartate and lactate. The presence of
multiple isotopomers was clearly observed in vivo, i.e.,
FIG. 3. AMARES quantification of
a Monte Carlo signal (SNR of 10,
linewidth of 5 Hz) using: (a) the
high-level prior knowledge (3rd
approach) and (b) medium-level
prior knowledge (2nd approach).
From bottom to top: estimate
superimposed on the original
Monte Carlo signal, estimate and
residue. The plotted regions were
focused on Glu and Gln C2, C3,
and C4 multiplets.
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the singlet (GluC4S) and doublet resonances (GluC4D43)
of GluC4 and the singlet (GluC3S), doublet (GluC3D1,
GluC3D2) and triplet (GluC3T1, GluC3T2, GluC3T3,
where T1, T2, and T3 represent the three lines of the tri-
plet) resonances for GluC3. The AMARES quantification
using high-level prior knowledge (3rd approach) is
shown in Fig. 4b. The fit matched the in vivo data as
shown by the flat residual. Since the low concentrated
metabolites such as g-aminobutyrate, N-acetylaspartate
and aspartate were not included in the fit, their resonan-
ces were present in the residual.
For the in vivo quantifications, we assessed first the
impact of prior knowledge by using AMARES combined
with low-level to high-level prior knowledge (i.e., the
results obtained using low and medium-level prior
knowledge were compared to those obtained using high-
level prior knowledge). Figure 5a shows the impact of
prior knowledge (AMARES combined with the 1st or 3rd
approach) on spectra acquired after 1 hour of [1,6-13C2]
glucose infusion (temporal resolution of 5.4 min in a 320
mL voxel). Figure 5b demonstrates the impact of prior
knowledge (using AMARES combined with the 1st or
3rd approach) on spectra acquired after 5 h of [1,6-13C2]
glucose infusion (temporal resolution of 5.4 min in a 320
mL voxel). As can be seen, the fit matched the in vivo
data when using the AMARES quantification with high-
level prior knowledge (3rd approach) for both spectra
acquired at different time points during the infusion.
However, when using the low-level prior knowledge (1st
FIG. 4. Quantification of a typical in vivo 13C MRS spectrum (a)
1H-localized 13C spectrum acquired in vivo on a rat brain after
infusion of [1,6-13C2]glucose in a voxel of 320 mL. The data was
acquired during 1 h, starting 5 h after the onset of glucose infu-
sion. b: AMARES quantification of the signal shown in (a). From
bottom to top: estimate superimposed on the original signal, esti-
mate and residue. A zoom was performed on Glu and Gln C3, C4,
and C2 multiplets.
FIG. 5. Quantification of an in vivo 13C MRS spectrum acquired with a temporal resolution of 5.4 min (a) after 1 h and (b) 5 h of infu-
sion. The upper pannel shows the quantification made using the 1st approach (singlet resonances) and the lower panel the quantifica-
tion using the 3rd approach (multiplet pattern with inclusion of phase distortions). The plotted regions were focused on Glu and Gln C2,
C3, and C4 multiplets.
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approach), the fit matched satisfactorily the data acquired
only in the first hour of infusion. For the spectra acquired
later, a substantial mismatch between the original spectra
and the fit was observed (Fig. 5b). Figure 6a shows the
impact of prior knowledge on the quantification of the
GluC4 position whereas Fig. 6b shows the impact of prior
knowledge on the labeling position GluC3. As for the
Monte Carlo study, when fitting the in vivo data with
AMARES combined with low-level prior knowledge (1st
approach), large fluctuations of the fitted data were
noticed (between 10 and 30%). When the medium-level
prior knowledge (2nd approach) was used, slight overesti-
mations ranging from 4 to 13% were obtained.
In a second step we compared the in vivo time courses
obtained using AMARES with high-level prior knowl-
edge (3rd approach, blue rhombus and red squares in
Fig. 7) with those obtained using LCModel (4th
approach, green triangles and orange circles in Fig. 7).
As can be seen from the in vivo time courses of Glu C4,
C3, C2 and Gln C4, C3, C2, the two approaches gave con-
sistent and highly similar results. Overall, the differences
between the two approaches were between 0 and 5%.
DISCUSSION
This study demonstrates that accurate quantification of
in vivo 13C isotopomers using AMARES combined with
a suitable incorporation of high-level prior knowledge is
possible. The degree of the prior knowledge necessary
for the quantification of in vivo 13C spectra using
AMARES was evaluated first with Monte Carlo simula-
tions using artificial input 13C MRS spectra and then on
in vivo 13C rat brain spectra. Finally, we compared
AMARES and LCModel for the quantification of in vivo
rat brain 13C spectra.
To validate AMARES for the quantification of 13C iso-
topomers, we first used Monte Carlo simulations which
showed that AMARES combined with high-level prior
knowledge (3rd approach) gave consistent and similar
results to the true values even at low SNR and large line-
widths (Fig. 2b,c). Note that even at a SNR of 1 the
obtained systematic errors were below 7% consistent
with previous observations (17). Moreover, identical
results to those in the Monte Carlo simulations were
obtained when AMARES combined with high-level prior
knowledge (3rd approach) was used to quantify in vivo
13C rat brain spectra (Figs. 6 and 7). To evaluate the reli-
ability of in vivo quantifications using the 3rd approach
(high-level prior knowledge) we compared our results to
those obtained using LCModel, which was previously
validated (17) as gold standard. Our data (Fig. 7) showed
that the results obtained with AMARES were identical
with those obtained with LCModel when high-level prior
knowledge was used. This result could be expected since
identical prior knowledge was used for both quantifica-
tion algorithms. The corresponding AMARES prior
knowledge files are provided as Supporting Information.
The high sensitivity and spectral resolution with con-
comitant AMARES quantification combined with high-
level prior knowledge indicated that the precision was
sufficient to allow the simultaneous measurement and
quantification of Glu C4, C3, C2 and Gln C4, C3, C2 with
a temporal resolution of 5.4 min in a 320 mL voxel.
To determine the degree of prior knowledge necessary
when using AMARES for the quantification of simulated
and in vivo 13C isotopomers measured in rat brain at
9.4T, we compared the results obtained using two differ-
ent approaches based on low and medium-level prior
knowledge to those obtained using high-level prior
knowledge. When reducing prior knowledge by fitting
FIG. 6. (a) Representative in vivo
time courses of GluC4 using
AMARES with the 1st (purple
circles), 2nd (green triangles) and
3rd (blue rhombus) approach; (b)
Representative in vivo time courses
of GluC3 using AMARES with the
1st (purple circles), 2nd (green trian-
gles) and 3rd (blue rhombus)
approach. [Color figure can be
viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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each resonance at a specific carbon position with a sin-
glet without taking the J-coupling pattern into account
(1st approach) a large fluctuation of the fitted data was
obtained combined with an underestimation of GluC4
(10%) and an overestimation of GluC3 (30%) for both
Monte Carlo and in vivo quantifications (Figs. 2 and 6).
The overestimation of GluC3 was attributed to the fitting
of a complex multiplet pattern by a singlet with large
linewidth.
When further improving the prior knowledge but
neglecting the information regarding the relative phase
due to homonuclear 13C-13C J-modulation occurring in
the DEPT sequence (2nd approach), only slight overesti-
mations ranging from 3 to 13% were obtained for both
Monte Carlo and in vivo studies (Figs. 2a and 6). The
relative phase due to homonuclear 13C-13C J-modulation
occurring in the DEPT sequence was discernable in
the spectra through the negative contributions in the
isotopomer lines (Fig. 3). When omitting this information
in the quantification, an overestimation of the metabolite
concentrations was noticed (Figs. 2a, 3b, and 6). More-
over, the relative contribution of the multiplets to each
carbon position was biased, potentially leading to errors
in the fractional enrichment of the carbon positions, if
calculated from the multiplets (when using the 2nd
approach).
Overall, the outcome of the Monte Carlo simulations
was highly consistent with the in vivo quantification
with respect to the importance of high-level prior knowl-
edge, demonstrating that fitting the signals arising from
different carbon positions with singlets and neglecting
the multiplets due to 13C-13C J-couplings might lead to
substantial errors in the quantification of the time
courses which would consequently lead to errors in the
estimated metabolic fluxes. These results were independ-
ent of the data quality, as demonstrated by our simula-
tions showing that the high-level prior knowledge gave
more accurate and reliable results than the 1st approach,
even at the lowest SNR values (Fig. 2d,e).
It is interesting to note that the quantification of the
time courses for the first hour of infusion was similar for
all the AMARES approaches used in this study. How-
ever, when the resonances ascribed to the 13C-13C J-cou-
pling started to have significant intensity, the time
courses using the 1st and 2nd approach were no longer
consistent, ascribed to the inadequate assumptions on
the structure of the resonances. Indeed, upon infusion of
[1,6-13C2] glucose, the fractional enrichment of the car-
bon positions and thus the probability of 13C isotopes in
adjacent positions increases. Consequently, the splitting
of resonances due to homonuclear 13C-13C scalar cou-
pling is more important. Using the GluC4D43/(GluC4Sþ
GluC4D43) ratio, a glutamate FE of about 20% at the C3
position was estimated after 1 h of [1,6-13C2] glucose
infusion. Based on our simulations and on the quantifi-
cation of time courses for the first hour of infusion (cor-
responding to a FE of 20%), this value of FE can be
considered as an upper threshold for obtaining similar
results from both 1st and 3rd approaches. Above this
value, the results obtained using the 3rd approach
should be more accurate. This observation is also valid
for [1-13C] glucose infusions, for which this critical FE
value is reached at later time points.
We conclude that accurate quantification of in vivo
13C isotopomers using AMARES combined with a suita-
ble incorporation of high-level prior knowledge is possi-
ble, leading to a more accurate and reliable quantifica-
tion of in vivo 13C spectra and to similar results to those
FIG. 7. Representative in vivo
time courses of Glu C4, C3, C2
and Gln C4, C3, C2 obtained
using AMARES with high-level
prior knowledge (3rd approach—
blue rhombus and red squares)
vs. LCModel (4th approach—
green triangles and orange
circles). [Color figure can be
viewed in the online issue,
which is available at
wileyonlinelibrary.com.]
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obtained with LCModel. In contrast, when using limited
prior knowledge, the results obtained with AMARES
were over/underestimated, demonstrating that fitting the
signals arising from different carbon positions with sin-
glets and neglecting the multiplets due to 13C-13C J-cou-
plings might lead to substantial errors in the quantifica-
tion of the time courses, which would consequently lead
to errors in the estimated metabolic fluxes.
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